Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which identified encouraging clinical activity in patients with ...

-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (QTTB) ("Q32 Bio"), a ...

-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very ...

Clinical trials are an essential part of medical breakthroughs that help patients, but getting them off the ground and running them is often fraught with challenges. Specifically, qualification, ...

Flexible electronics have been drawing significant attention for healthcare applications and show great promise for monitoring of blood circulation (e.g., postoperative monitoring of free flaps).